By reiterating its revenue guidance for 2024, Codexis demonstrates confidence in its business operations and product pipeline, excluding PAXLOVID. This reaffirmation could positively influence investor sentiment by highlighting the company's stability and growth prospects outside of its PAXLOVID-related revenue. The specific exclusion of PAXLOVID revenue suggests that Codexis is focusing on the strength and potential of its broader product portfolio, which could be seen as a positive indicator of its underlying business health and future revenue streams.